Investing in a healthy future
Generating superior returns by investing in and building sustainable and leading healthcare businesses
With a Nordic base
Impilo is an investment company focused on investments in Nordic companies operating in the pharmaceutical, medical techonology, healthcare and care services and other health-related industries
Redefining success
Our starting point is that our portfolio companies must contribute to a positive and sustainable development of the societies and markets in which they operate, in order to remain successful in the long-term
Investments
We invest in companies to which we can offer knowledge, capital and new perspectives and thus create momentum to implement change and achieve ambitious goals. Our portfolio consists of market-leading healthcare companies with significant growth potential in the Nordics and beyond.
Our team
Who we are
At Impilo, we are a diverse team with the necessary sector-specific knowledge, experience, and passion to be a responsible and active partner to the companies in which we invest in. We believe that our employees are our most important assets and seek to create a workplace where the team is more important than the individual.
News
Impilo’s portfolio company Decon acquires Acekare – a French-based manufacturer and distributor of mobility assistance solutions
The acquisition of Acekare marks an important step in Decon’s strategic ambition to build a leading European niche mobility platform by adding a complementary product company to its existing offering and establishing a direct presence in the French market
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo completes the acquisition of Oticon Medical
We are pleased to announce that Impilo has today completed the acquisition of Oticon Medical from Demant A/S. This marks the first investment in our recently raised Fund II.
U.S. FDA has granted accelerated approval of Loargys®
Immedica today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Loargys® (pegzilarginase-nbln), an arginine specific enzyme indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction.